What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Trump pharmaceutical tariff threat lessens after Pfizer deal
U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla (L) as he announces a deal with…
Pfizer’s new obesity bet, Metsera, releases drug data
Thomas Fuller | SOPA Images | Lightrocket | Getty Images A version of this article first appeared in…
Eli Lilly plans $6.5 billion Texas manufacturing plant for obesity pill
A rendering of Eli Lilly’s manufacturing facility in Houston, Texas. Courtesy: Eli Lilly Eli Lilly on Tuesday said…
Eli Lilly to build $5 billion Virginia manufacturing facility
Eli Lilly Biotechnology Center is shown in San Diego, California, March 1, 2023. Mike Blake | Reuters Eli…
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy…
CPI report health care inflation rises
Jose Luis Pelaez Inc | Digitalvision | Getty Images Health-care inflation is fueling higher coverage costs, setting the…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Wegovy-maker Novo Nordisk to cut around 9,000 jobs
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg |…
Novo Nordisk’s Martin Holst Lange previews obesity pill
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news…
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart…
Eli Lilly’s Daniel Skovronsky talks obesity pill data
The Eli Lilly headquarters in Indianapolis, Indiana, on Aug. 15, 2024. AJ Mast | Bloomberg | Getty Images…